Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36

被引：2

作者：

Xie, Xiulong ^{[1
,2
,3
]}

Niu, Zhenlan ^{[1
]}

Wang, Linlin ^{[1
]}

Zhou, Xiaofei ^{[1
]}

Yu, Xingyan ^{[1
,2
,3
]}

Jing, Hongyan ^{[1
,3
]}

Yang, Yi ^{[1
,3
]}

机构：

[1] Biocytogen Pharmaceut Beijing, 12 Baoshen South St, Beijing 102600, Peoples R China

[2] Jiangxi Univ Chinese Med, 1688 Meiling Ave, Nanchang 330004, Jiangxi, Peoples R China

[3] Yangtze Delta Drug Adv Res Inst, 100 Dongtinghu Rd, Haimen 226133, Jiangsu, Peoples R China

来源：

EXPERIMENTAL ANIMALS | 2023年 / 72卷 / 04期

关键词：

CD36; colon cancer; humanized mouse model; immunotherapy; monoclonal antibody; EXPRESSION; GENE;

D O I：

10.1538/expanim.23-0021

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

CD36 (also known as scavenger receptor B2) is a multifunctional receptor that mediates lipid uptake, advanced oxidation protein products, and immunological recognition, and has roles in lipid accumulation, apoptosis, as well as in metastatic colonization in cancer. CD36 is involved in tumor immunity, metastatic invasion, and therapy resistance through various molecular mechanisms. Targeting CD36 has emerged as an effective strategy for tumor immunotherapy. In this study, we have successfully generated a novel hCD36 mouse (Unless otherwise stated, hCD36 mouse below refer to homozygous hCD36 mouse) strain where the sequences encoding the extracellular domains of the mouse Cd36 gene were replaced with the corresponding human sequences. The results showed that the hCD36 mice only expressed human CD36, and the proportion of each lymphocyte was not significantly changed compared with wild-type mice. Furthermore, CD36 monoclonal antibody could significantly inhibit tumor growth after treatment. Therefore, the hCD36 mouse represent a validated preclinical mouse model for the evaluation of tumor immunotherapy targeting CD36.

引用

页码：535 / 545

页数：11